Eli Lilly and Company or Alkermes plc: Who Invests More in Innovation?

Eli Lilly's R&D spending dwarfs Alkermes by 60x.

__timestampAlkermes plcEli Lilly and Company
Wednesday, January 1, 201477530004733600000
Thursday, January 1, 201540190004796400000
Friday, January 1, 201623010005243900000
Sunday, January 1, 201772320005281800000
Monday, January 1, 2018688950005051200000
Tuesday, January 1, 2019528160005595000000
Wednesday, January 1, 202019460006085700000
Friday, January 1, 202110200007025900000
Saturday, January 1, 20223938420007190800000
Sunday, January 1, 20232708060009313400000
Monday, January 1, 202424532600014271000000
Loading chart...

Cracking the code

Innovation Investment: Eli Lilly vs. Alkermes

In the competitive world of pharmaceuticals, innovation is key. Eli Lilly and Company and Alkermes plc are two giants in the industry, each with a unique approach to research and development (R&D). Over the past decade, Eli Lilly has consistently outpaced Alkermes in R&D spending, investing nearly 60 times more on average. In 2023, Eli Lilly's R&D expenses reached a staggering $9.3 billion, marking a 97% increase from 2014. In contrast, Alkermes' investment peaked at $393 million in 2022, a significant rise from its 2014 figure but still a fraction of Eli Lilly's commitment.

This disparity highlights Eli Lilly's aggressive strategy to lead in innovation, while Alkermes focuses on more targeted investments. As the pharmaceutical landscape evolves, these investment patterns will shape the future of drug development and patient care.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025